"Epoprostenol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).
- Prostaglandin I2
- Prostaglandin I(2)
- Epoprostenol Sodium
- Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer
Below are MeSH descriptors whose meaning is more general than "Epoprostenol".
Below are MeSH descriptors whose meaning is more specific than "Epoprostenol".
This graph shows the total number of publications written about "Epoprostenol" by people in this website by year, and whether "Epoprostenol" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Epoprostenol" by people in Profiles.
Merideth FL, Quinn DK. "Walking the Walk": Decisional Capacity Deficits After Right Hemisphere Subdural Hematoma. Psychosomatics. 2016 Jan-Feb; 57(1):102-6.
Raghunathan K, Connelly NR, Robbins LD, Ganim R, Hochheiser G, DiCampli R. Inhaled epoprostenol during one-lung ventilation. Ann Thorac Surg. 2010 Mar; 89(3):981-3.
Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest. 2006 Nov; 130(5):1481-8.
Daley JT, Brown ML, Watkins T, Traish AM, Huang YH, Moreland RB, De Tejada IS. Prostanoid production in rabbit corpus cavernosum: I. regulation by oxygen tension. J Urol. 1996 Apr; 155(4):1482-7.
Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, Michelson AD. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest. 1996 Feb 15; 97(4):979-87.
Weber C, Kruse HJ, Sellmayer A, Erl W, Weber PC. Platelet activating factor enhances receptor-operated Ca(++)-influx and subsequent prostacyclin synthesis in human endothelial cells. Biochem Biophys Res Commun. 1993 Sep 15; 195(2):874-80.
Siess W, Boehlig B, Weber PC, Lapetina EG. Prostaglandin endoperoxide analogues stimulate phospholipase C and protein phosphorylation during platelet shape change. Blood. 1985 May; 65(5):1141-8.
Stoff JS, MacIntyre DE, Brown RS, Salzman EW. Prostacyclin overproduction in Bartter's syndrome. Lancet. 1979 Dec 01; 2(8153):1169-7.